A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies

Inclusion Criteria:

- Histologic proof of lymphoid malignancy with an expected complete response rate of
less than 20 percent OR have failed at least one prior therapy.

- No chemotherapy within 3 weeks of entry into study and must have recovered from acute
toxic effects of prior therapy.

- Life expectancy of at least 12 weeks.

- Performance status equal to or less than Zubrod 2.

- Signed informed consent.

- Patients with measurable disease.

- Age at least 16 years.

- Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined
as AGC greater than 1500 and platelet count greater than 100,000.

- Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT
less than or equal to 4 times the upper limits of normal.

- Adequate renal function defined as serum creatine less than or equal to 1.5 mg %.

Exclusion Criteria:

- No serious intercurrent illness.

- Adequate contraception (if applicable).

- NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA)
class III or IV.

- NO experimental clinical trial within 3 weeks of study entry.

- NO patients with active CNS disease.

- Full recovery from any prior surgical treatment.

- NO active active infections.